MedTrace Logo

Oxaloacetate Pharmacokinetics and Safety

NCT02063308 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2014-07-24

No results posted yet for this study

Summary

By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any side-effects.

Conditions

Interventions

DIETARY_SUPPLEMENT

Oxaloacetate (OAA)

Sponsors & Collaborators

  • Russell Swerdlow, MD

    lead OTHER

Principal Investigators

  • Russell Swerdlow, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02063308 on ClinicalTrials.gov